Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 2/20 | 0.46 |
| ▸ | HTR6 | P50406 | 3/20 | 0.46 |
| ▸ | HTR1D | P28221 | 3/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.41 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12384216 | 0.87 | HTR7 (0.57) | HTR7KIF11 | |
| SCHEMBL4937376 | 0.82 | HTR6 (0.54) | HTR7HTR6ERBB2 | |
| SCHEMBL4941461 | 0.81 | HTR6 (0.71) | HTR6HTR1DERBB2KIF11 | |
| SCHEMBL4940378 | 0.81 | CYP2A6 (0.44) | HTR7HTR6KIF11 | |
| SCHEMBL4942424 | 0.81 | TRPV1 (0.48) | HTR6HTR1DKIF11 | |
| SCHEMBL18857011 | 0.77 | KRAS (0.44) | HTR7HTR6ERBB2 | |
| SCHEMBL20353866 | 0.77 | HTR7 (0.44) | HTR7PTGER3 | |
| SCHEMBL4942460 | 0.76 | TLR8 (0.47) | GRIN2BERBB2 | |
| SCHEMBL24144949 | 0.73 | HTR7 (0.53) | HTR7KIF11 | |
| SCHEMBL12605578 | 0.73 | HTR2C (0.63) | HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214647-A1 | SUBSTITUTED INDOLE ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | WYETH (US) | 2008-09-04 | — | — | US | disclosed |
| US-7368471-B2 | Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH (US) | 2008-05-06 | — | — | US | disclosed |
| EP-1844771-A2 | Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | Wyeth (US) | 2007-10-17 | — | — | EP | disclosed |
| EP-1397130-B1 | SUBSTITUTED INDOLE ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | WYETH CORP (US) | 2007-07-25 | — | — | EP | disclosed |
| US-20060167059-A1 | Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH (US) | 2006-07-27 | — | — | US | disclosed |
| US-7074817-B2 | Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH (US) | 2006-07-11 | — | — | US | disclosed |
| US-20030125371-A1 | Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH | 2003-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214647-A1 | SUBSTITUTED INDOLE ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | SERPINE1, TFPI, F12 | HTR7 673/4885HTR6 577/4885HTR1D 239/4885 |
| US-20060167059-A1 | Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | SERPINE1, TFPI, F12 | HTR7 666/4885HTR6 566/4885HTR1D 236/4885 |
| US-20030125371-A1 | Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | TFPI, SERPINE1, PLAT | HTR7 414/4885HTR6 291/4885HTR1D 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.